Options for systemic therapy of uveitis including alternative therapies

References

• Gonzalez MM, Solano MM, Porco TC, et al. Epidemiology of uveitis in a US population-based study. J Ophthalmic Inflamm Infect. 2018 Apr 17;8(1):6. doi: 10.1186/s12348-018-0148-5
   PubMedGoogle Scholar
• Zhang Y, Amin S, Lung KI, et al. Incidence, prevalence, and risk factors of infectious uveitis and scleritis in the United States: a claims-based analysis. PLoS One. 2020;15(8):e0237995. doi: 10.1371/journal.pone.0237995
   PubMed Web of Science ®Google Scholar
• Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in Non-infectious Uveitis: a systematic review. Front Med. 2021;8:695904. doi: 10.3389/fmed.2021.695904
   PubMed Web of Science ®Google Scholar
• Forrester JV. Uveitis: pathogenesis. Lancet. 1991 Dec 14;338(8781):1498–501.
   PubMed Web of Science ®Google Scholar
• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332–6.
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996 Sep;80(9):844–8. doi: 10.1136/bjo.80.9.844
   PubMed Web of Science ®Google Scholar
• AlBloushi AF, Alfawaz AM, Al-Dahmash SA, et al. Incidence, risk factors and surgical outcomes of cataract among patients with uveitis in a University Referral Hospital in Riyadh, Saudi Arabia. Ocul Immunol Inflamm. 2019;27(7):1105–1113. doi: 10.1080/09273948.2018.1504970
   PubMed Web of Science ®Google Scholar
• Herbert HM, Viswanathan A, Jackson H, et al. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma. 2004 Apr;13(2):96–9.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. Surv Ophthalmol. 1997 Mar;41(5):361–394.
   PubMed Web of Science ®Google Scholar
• Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008 Dec;10(12):1–23.
   PubMedGoogle Scholar
• Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993 Jan 28;328(4):246–252.
   PubMed Web of Science ®Google Scholar
• Shelley BM, Sussman AL, Williams RL, et al. ‘They don’t ask me so I don’t tell them’: patient-clinician communication about traditional, complementary, and alternative medicine. Ann Fam Med. 2009 Mar;7(2):139–47.
   PubMed Web of Science ®Google Scholar
• Couret C, Ducloyer JB, Touhami S, et al. Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis. J Fr Ophtalmol. 2020 Apr;43(4):341–361.
   PubMed Web of Science ®Google Scholar
• Babu K, Mahendradas P. Medical management of uveitis–current trends. Indian J Ophthalmol. 2013 Jun;61(6):277–83. doi: 10.4103/0301-4738.114099
   PubMed Web of Science ®Google Scholar
• McGhee CN. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992 Nov;76(11):681–4. doi: 10.1136/bjo.76.11.681
   PubMed Web of Science ®Google Scholar
• Vegas-Revenga N, Martín-Varillas JL, Calvo-Río V, et al. Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. Clin Exp Rheumatol. 2022 Jan;40(1):142–149.
   PubMed Web of Science ®Google Scholar
• Schnabel A, Unger E, Brück N, et al. High-dose intravenous methylprednisolone in juvenile non-infectious uveitis: A retrospective analysis. Clin Immunol. 2020 Feb;211:108327.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009 Oct;148(4):500–509.e2.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet’s disease. Arthritis Care Res (Hoboken). 2010 Dec;62(12):1733–8.
   PubMed Web of Science ®Google Scholar
• Pacheco PA, Taylor SR, Cuchacovich MT, et al. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm. 2008 Jul;16(4):161–165.
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmol. 2008 Oct;115(10):1826–32.
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmol. 2001 Jun;108(6):1134–9.
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmol. 2009 Nov;116(11):2188–98e1.
   PubMed Web of Science ®Google Scholar
• Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14 Suppl 1:s2–8.
   PubMed Web of Science ®Google Scholar
• Teoh SC, Hogan AC, Dick AD, et al. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008 Nov;146(5):752–60, 760.e1–3.
   Web of Science ®Google Scholar
• Ali S, Kharel Sitaula R, Biswas J. Efficacy and safety of Mycophenolate Mofetil in the treatment of recalcitrant intermediate uveitis. Ocul Immunol Inflamm. 2019;27(5):851–857. doi: 10.1080/09273948.2018.1453524
   PubMed Web of Science ®Google Scholar
• Bhat P, Cervantes-Castañeda RA, Doctor PP, et al. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm. 2009 May;17(3):185–90.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM A, Hemachandran S, HS A-M, et al. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2012 Dec;90(8):e603–8.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM A, Dosari M, Hemachandran S, et al. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2017 Feb;95(1):85–90.
   PubMed Web of Science ®Google Scholar
• Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmol. 2008 Aug;115(8):1416–21, 1421 e1.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA. 2019 Sep 10;322(10):936–945. doi: 10.1001/jama.2019.12618
   PubMed Web of Science ®Google Scholar
• Tsui E, Rathinam SR, Gonzales JA, et al. Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as steroid-sparing treatment uveitis trial. Ophthalmol. 2022 Jun;129(6):661–667.
   PubMed Web of Science ®Google Scholar
• Bui AD, Kong CL, Kelly NK, et al. Time to Uveitis Control with methotrexate and Mycophenolate Mofetil. Ophthalmol. 2022 Jun;129(6):721–723.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81.
   PubMedGoogle Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005 May;89(5):533–536.
   PubMed Web of Science ®Google Scholar
• Alizadegan F, Yalcinbayir O, Ucan Gunduz G, et al. Infliximab therapy in Behçet’s uveitis. J Fr Ophtalmol. 2022 Nov;45(9):1036–1041.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Vitale A, et al. Ten-year Retention Rate of Infliximab in patients with Behcet’s disease-related uveitis. Ocul Immunol Inflamm. 2019;27(1):34–39.
   PubMed Web of Science ®Google Scholar
• Handa T, Tsunekawa H, Yoneda M, et al. Long-term remission of ocular and extraocular manifestations in Behcet’s disease using infliximab. Clin Exp Rheumatol. 2011 Jul;29(4 Suppl 67):S58–63.
   PubMed Web of Science ®Google Scholar
• Kruh JN, Yang P, Suelves AM, et al. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmol. 2014 Jan;121(1):358–364.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009 Jun;127(6):819–822.
   PubMed Web of Science ®Google Scholar
• Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007 Dec;144(6):844–849.
   PubMed Web of Science ®Google Scholar
• Richards JC, Tay-Kearney ML, Murray K, et al. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005 Oct;33(5):461–8.
   PubMed Web of Science ®Google Scholar
• Miraldi Utz V, Bulas S, Lopper S, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Pediatr Rheumatol Online J. 2019 Nov 29;17(1):79. doi: 10.1186/s12969-019-0383-9
   PubMed Web of Science ®Google Scholar
• Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmol. 2006 May;113(5):860–4.e2.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Jaffe GJ, Fortin E, et al. Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmol. 2021 Jun;128(6):899–909.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi: 10.1056/NEJMoa1509852
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with Noninfectious Uveitis in an ongoing open-label study: VISUAL III. Ophthalmol. 2018 Jul;125(7):1075–1087.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006 Jul;54(7):2136–2146.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009 May;68(5):696–701.
   PubMed Web of Science ®Google Scholar
• Bober E, Frain K, Fotuhi M, et al. Adalimumab in the treatment of refractory non-infectious scleritis: 6-month outcomes. Eye (Lond). 2024 Feb;38:628–630.
   PubMedGoogle Scholar
• Evereklioglu C, Sonmez HK, Sevim DG, et al. Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular behçet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation. Int Ophthalmol. 2023 Aug 9;43(12):4461–4472. doi: 10.1007/s10792-023-02846-4
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017 Apr 27;376(17):1637–1646. doi: 10.1056/NEJMoa1614160
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martin-Varillas JL, Calvo-Rio V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behcet’s disease: national multicenter study of 177 cases. Arthritis & Rheumat. 2019 Dec;71(12):2081–2089.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011 Apr;63(4):612–8.
   PubMed Web of Science ®Google Scholar
• Ashkenazy N, Saboo US, Abraham A, et al. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis. J AAPOS. 2019 Jun;23(3):e151 1–e151 5.
   Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019 Feb;38(2):407–415.
   PubMed Web of Science ®Google Scholar
• Lejoyeux R, Diwo E, Vallet H, et al. INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema. Ocul Immunol Inflamm. 2018;26(7):991–996. doi: 10.1080/09273948.2018.1498110
   PubMed Web of Science ®Google Scholar
• Liu W, Bai D, Kou L. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis. BMC Ophthalmol. 2023 May 29;23(1):240.
   PubMed Web of Science ®Google Scholar
• Kramer M, Monselise Y, Bahar I, et al. Serum cytokine levels in active uveitis and remission. Curr Eye Res. 2007 Jul;32(7–8):669–75.
   PubMed Web of Science ®Google Scholar
• Uludag G, Karaca I, Akhavanrezayat A, et al. Efficacy and safety of Tocilizumab in the management of non-infectious uveitis failed with conventional immunomodulatory and anti-TNFα therapies. Ocul Immunol Inflamm. 2022 Dec;21:1–7.
   Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014 Jul;32(4 Suppl 84):S75–9.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the STOP-Uveitis study: evaluating the safety, tolerability, and efficacy of Tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017 Nov;183:71–80.
   PubMed Web of Science ®Google Scholar
• Sadiq MA, Hassan M, Afridi R, et al. Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study. Int J Retina Vitreous. 2020;6(1):47. doi: 10.1186/s40942-020-00245-w
   PubMedGoogle Scholar
• Mesquida M, Molins B, Llorenc V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmol. 2014 Dec;121(12):2380–6.
   PubMed Web of Science ®Google Scholar
• Leclercq M, Andrillon A, Maalouf G, et al. Anti-tumor necrosis factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: a multicenter study from the French Uveitis Network. Ophthalmol. 2022 May;129(5):520–529.
   PubMed Web of Science ®Google Scholar
• Khitri MY, Bartoli A, Maalouf G, et al. Tocilizumab in Behçet disease: a multicenter study of 30 patients. J Rheumatol. 2023 Mar 1;50(7):916–923. doi: 10.3899/jrheum.221106
   PubMed Web of Science ®Google Scholar
• Marino A, Marelli L, Nucci P, et al. Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis. Ocul Immunol Inflamm. 2023Jan;19:1–4.
   Google Scholar
• Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019 Sep 16;9(1):17. doi: 10.1186/s12348-019-0182-y
   PubMed Web of Science ®Google Scholar
• Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and safety of Sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmol. 2019 Mar;126(3):428–437.
   PubMed Web of Science ®Google Scholar
• Ng CC, Sy A, Cunningham ET Jr. Rituximab for non-infectious uveitis and scleritis. J Ophthalmic Inflamm Infect. 2021 Aug 16;11(1):23.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM A, Dheyab A, Khatib D, et al. Efficacy of B cell depletion therapy with Rituximab in refractory chronic recurrent uveitis associated with Vogt-Koyanagi-Harada Disease. Ocul Immunol Inflamm. 2022 Apr 3;30(3):750–757.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016 Jun;100(6):782–6.
   PubMed Web of Science ®Google Scholar
• Bayry J, Misra N, Latry V, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003 Jun;10(3):165–9.
   PubMed Web of Science ®Google Scholar
• Garcia-Geremias M, Carreño E, Epps SJ, et al. Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis. Int Ophthalmol. 2015 Apr;35(2):281–5.
   PubMed Web of Science ®Google Scholar
• Onal S, Foster CS, Ahmed AR. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm. 2006 Dec;14(6):367–74. doi: 10.1080/09273940601025966
   PubMed Web of Science ®Google Scholar
• Ediriwickrema LS, Chhadva P, Rodger DC, et al. Intravenous immunoglobulin in the treatment of juvenile retinitis pigmentosa-associated cystoid macular edema and uveitis. Retin Cases Brief Rep. 2018 Summer;12(3):242–246.
   PubMedGoogle Scholar
• Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol. 1999 Apr;117(4):471–477.
   PubMed Web of Science ®Google Scholar
• LeHoang P, Cassoux N, George F, et al. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm. 2000 Mar;8(1):49–57.
   PubMed Web of Science ®Google Scholar
• Seider N, Beiran I, Scharf J, et al. Intravenous immunoglobulin therapy for resistant ocular Behcet’s disease. Br J Ophthalmol. 2001 Nov;85(11):1287–8.
   PubMed Web of Science ®Google Scholar
• Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013 Jul;27(3):171–8. doi: 10.1016/j.tmrv.2013.05.004
   PubMed Web of Science ®Google Scholar
• Guo Y, Tian X, Wang X, et al. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299. doi: 10.3389/fimmu.2018.01299
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol. 1985 Winter;1(4):369–82. doi: 10.1089/jop.1985.1.369
   PubMedGoogle Scholar
• Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol. 2010 Jan;58(1):55–8. doi: 10.4103/0301-4738.58472
   PubMed Web of Science ®Google Scholar
• Isnard Bagnis C, du Montcel S T, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002 Dec;13(12):2962–2968.
   PubMed Web of Science ®Google Scholar
• Figueroa MS, Ciancas E, Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol. 2007 Jan;17(1):69–74. doi: 10.1177/112067210701700110
   PubMed Web of Science ®Google Scholar
• Luis J, Alsaedi A, Phatak S, et al. Efficacy of tacrolimus in uveitis, and the usefulness of serum tacrolimus levels in predicting disease control. Results from a single large center. Ocul Immunol Inflamm. 2022 Oct;30(7–8):1654–1658.
   PubMed Web of Science ®Google Scholar
• Wakefield D. Does cyclophosphamide still have a role in the treatment of severe inflammatory eye disease? Ocul Immunol Inflamm. 2014 Aug;22(4):306–10. doi: 10.3109/09273948.2013.854395
   PubMed Web of Science ®Google Scholar
• Ahmed A, Foster CS. Cyclophosphamide or Rituximab Treatment of Scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res. 2019;61(1):44–50. doi: 10.1159/000486791
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol. 1994 Jan;21(1):123–5.
   PubMed Web of Science ®Google Scholar
• Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmol. 2010 Feb;117(2):356–65.
   PubMed Web of Science ®Google Scholar
• Baker GL, Kahl LE, Zee BC, et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med. 1987 Jul;83(1):1–9.
   PubMed Web of Science ®Google Scholar
• Baltus JA, Boersma JW, Hartman AP, et al. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis. 1983 Aug;42(4):368–73.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008 Dec;146(6):802–12.e1.
   PubMed Web of Science ®Google Scholar
• Godfrey WA, Epstein WV, O’Connor GR, et al. The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol. 1974 Sep;78(3):415–28.
   PubMed Web of Science ®Google Scholar
• Mamo JG, Azzam SA. Treatment of Behçet’s disease with chlorambucil. Arch Ophthalmol. 1970 Oct;84(4):446–450.
   PubMed Web of Science ®Google Scholar
• Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet’s disease. Ocul Immunol Inflamm. 2001 Dec;9(4):219–29.
   PubMed Web of Science ®Google Scholar
• Dinning WJ, Perkins ES. Immunosuppressives in uveitis. A preliminary report of experience with chlorambucil. Br J Ophthalmol. 1975 Aug;59(8):397–403. doi: 10.1136/bjo.59.8.397
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts eye and ear infirmary experience. Ophthalmol. 2002 Jan;109(1):137–42.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Synoverska O, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021 Nov 27;398(10315):1984–1996. doi: 10.1016/S0140-6736(21)01255-1
   PubMed Web of Science ®Google Scholar
• Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27(8):1232–1234. doi: 10.1080/09273948.2019.1605453
   PubMed Web of Science ®Google Scholar
• Dutta Majumder P, Shah A, Kaushik V. Tofacitinib in Vogt-Koyanagi-Harada disease. Indian J Ophthalmol. 2020 Sep;68(9):1938–1939. doi: 10.4103/ijo.IJO_998_20
   PubMed Web of Science ®Google Scholar
• Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019Mar; 13:53–55.
   PubMedGoogle Scholar
• Zhang S, Cai Z, Mo X, et al. Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients. Pediatr Rheumatol Online J. 2021 Nov 15;19(1):160. doi: 10.1186/s12969-021-00634-x
   PubMed Web of Science ®Google Scholar
• Manoharan A, Atmakur H, Dutta Majumder P, et al. Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib. J Ophthalmic Inflamm Infect. 2023 Sep 27;13(1):45. doi: 10.1186/s12348-023-00359-w
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Murakami T, Nishitsuka K, et al. Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and uveitis: a case report. Front Med. 2021;8:764067.
   Web of Science ®Google Scholar
• Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021 Oct 9;22(1):689. doi: 10.1186/s13063-021-05651-5
   PubMed Web of Science ®Google Scholar
• Baquet-Walscheid K, Heinz C, Rath T, et al. Beneficial effect of Upadacitinib in an adult patient with Juvenile Idiopathic Arthritis-associated Uveitis after unsatisfactory response to Tofacitinib: A case report. Ocul Immunol Inflamm. 2023 Jul;31(5):1079–1080.
   PubMed Web of Science ®Google Scholar
• Tao T, He D, Peng X, et al. Successful remission with upadacitinib in two patients with anti-TNF-Refractory Macular Edema Associated with Behcet’s uveitis. Ocul Immunol Inflamm. 2023Oct; 6:1–4.
   Google Scholar
• Kötter I, Eckstein AK, Stübiger N, et al. Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol. 1998 May;82(5):488–494.
   PubMed Web of Science ®Google Scholar
• Pivetti-Pezzi P, Accorinti M, Pirraglia MP, et al. Interferon alpha for ocular Behçet’s disease. Acta Ophthalmol Scand. 1997 Dec;75(6):720–722.
   PubMedGoogle Scholar
• Feron EJ, Rothova A, van Hagen PM, et al. Interferon-alpha 2b for refractory ocular Behçet’s disease. Lancet. 1994 Jun 4;343(8910):1428.
   PubMed Web of Science ®Google Scholar
• Guillaume-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet’s disease. Rheumatology (Oxford). 2007 Oct;46(10):1570–1573.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee CS, Lee SC. Interferon alpha-2a treatment for refractory behcet uveitis in Korean patients. BMC Ophthalmol. 2018 Feb 20;18(1):52.
   PubMedGoogle Scholar
• Yang P, Huang G, Du L, et al. Long-term efficacy and Safety of Interferon Alpha-2a in the treatment of Chinese patients with Behcet’s uveitis not responding to conventional therapy. Ocul Immunol Inflamm. 2019;27(1):7–14.
   PubMed Web of Science ®Google Scholar
• Celiker H, Kazokoglu H, Direskeneli H. Long-term efficacy of pegylated interferon alpha-2b in Behcet’s Uveitis: a Small Case Series. Ocul Immunol Inflamm. 2019;27(1):15–22.
   PubMed Web of Science ®Google Scholar
• De Simone L, Invernizzi A, Aldigeri R, et al. Effectiveness of infliximab and interferon alpha-2a for the Treatment of Behcet’s uveitis: customizing therapy according to the clinical features. Ocul Immunol Inflamm. 2022 Feb 17;30(2):506–514.
   PubMed Web of Science ®Google Scholar
• Fardeau C, Simon A, Rodde B, et al. Interferon-alpha2a and systemic corticosteroid in monotherapy in chronic uveitis: results of the randomized controlled BIRDFERON study. Am J Ophthalmol. 2017 May;177:182–194.
   PubMed Web of Science ®Google Scholar
• Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul Immunol Inflamm. 2012 Apr;20(2):86–90. doi: 10.3109/09273948.2011.645989
   PubMed Web of Science ®Google Scholar
• Sobaci G, Bayraktar Z, Bayer A. ORIGINAL ARTICLE, interferon alpha-2A treatment for Serpiginous Choroiditis. Ocul Immunol Inflamm. 2005 Feb;13(1):59–66. doi: 10.1080/09273940490518865
   PubMed Web of Science ®Google Scholar
• Velazquez-Villoria D, Macia-Badia C, Segura-Garcia A, et al. Efficacy of immunomodulatory therapy with interferon-beta or glatiramer acetate on multiple sclerosis-associated uveitis. Arch Soc Esp Oftalmol. 2017 Jun;92(6):273–279.
   PubMedGoogle Scholar
• Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005 Oct;89(10):1254–1257.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013 Sep;156(3):478–486 e1.
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology. 2002 Nov 26;59(10):1496–1506.
   PubMed Web of Science ®Google Scholar
• Ebers GC. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group. Lancet. 1998 Nov 7;352(9139):1498–1504.
   PubMed Web of Science ®Google Scholar
• Radomska-Lesniewska DM, Osiecka-Iwan A, Hyc A, et al. Therapeutic potential of curcumin in eye diseases. Cent Eur J Immunol. 2019;44(2):181–189. doi: 10.5114/ceji.2019.87070
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Giuffre C, Cicinelli MV, et al. Oral phospholipidic curcumin in juvenile idiopathic arthritis-associated uveitis. Eur J Ophthalmol. 2020 Nov;30(6):1390–1396.
   PubMed Web of Science ®Google Scholar
• Lal B, Kapoor AK, Asthana OP, et al. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res. 1999 Jun;13(4):318–22.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 Jul;21(4b):2895–900.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007 Nov;4(6):807–18.
   PubMed Web of Science ®Google Scholar
• Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998 May;64(4):353–6.
   PubMed Web of Science ®Google Scholar
• Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin Ophthalmol. 2010 Oct 21;4:1201–1206.
   PubMedGoogle Scholar
• Allegri P, Rosa R, Masala A, et al. Clinical effectiveness of a new oral curcumin formulation in acute non-infectious uveitic macular edema: a 12-month observational study. Eur Rev Med Pharmacol Sci. 2022 Jan;26(1):46–53.
   PubMed Web of Science ®Google Scholar
• Allegri P, Cimino L, Davis JL, et al. Assessment of the anti-inflammatory effects of NORFLO® ORO in acute relapses of HLA-B27-associated autoimmune uveitis: a multicenter, randomized, placebo-controlled, double-blind clinical study. Ocul Immunol Inflamm. 2023 Apr;31(3):526–535.
   PubMed Web of Science ®Google Scholar
• Bhat AK, Krishnakumar V. Ayurvedic management of recurrent anterior uveitis (Raktaja adhimantha) with bloodletting therapy: A case report. J Ayurveda Case Reports. 2021;4(2):54–57.
   Google Scholar
• Shilpa S, SMP K. An Ayurvedic approach to non infectious choroiditis–prospective single case study. J Ayurveda Integr Med Sci. 2019 Oct 31;4(5):366–370.
   Google Scholar
• CT N, Sujathamma K. Anterior Uveitis and management in Ayurveda–A Case Study. J Ayurveda Integr Med Sci. 2017 Oct 31;2(5):206–210.
   Google Scholar
• Pushpa RP, Ashwini MJ. Ayurvedic management of acute anterior uveitis (Pittaja Adhimantha): a case study. Int J Res Ayurveda Pharm. 2018;9(2):113–117.
   Google Scholar
• Telgote D, Dakhore J, Waghmare R. Management of the juvenile idiopathic arthritis (JIA) associated anterior uveitis with special references to Pittaja Adhimantha, by an Ayurvedic and modern aspect-a single case study. Int J Res Indian Med. 2022;6(4):1–7.
   Google Scholar
• Yang Y, Wang Q, Xie M, et al. Berberine exerts an anti-inflammatory role in ocular Behcet’s disease. Mol Med Rep. 2017 Jan;15(1):97–102.
   PubMed Web of Science ®Google Scholar
• Yang Y, Qi J, Wang Q, et al. Berberine suppresses Th17 and dendritic cell responses. Invest Ophthalmol Vis Sci. 2013 Apr 5;54(4):2516–22. doi: 10.1167/iovs.12-11217
   PubMed Web of Science ®Google Scholar
• Li M, Chen X, Liu J, et al. Treatment of experimental autoimmune uveoretinitis with different natural compounds. Mol Med Rep. 2016 Jun;13(6):4654–8.
   PubMed Web of Science ®Google Scholar
• Du Z, Wang Q, Huang X, et al. Effect of berberine on spleen transcriptome and gut microbiota composition in experimental autoimmune uveitis. Int Immunopharmacol. 2020 Apr;81:106270.
   PubMed Web of Science ®Google Scholar
• Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63(4):201–8. doi: 10.1159/000243932
   PubMedGoogle Scholar
• Deng Z, Wu YF, Jiang L, et al. Matrine eye fluid regulates TLR4/NF- B pathway and affects the expression of cytokines associated with experimental uveitis in rabbits. Chin J Gen Pract. 2020;18(4):568–572.
   Google Scholar
• Li S, Liu F, Zhang K, et al. Research progress on the mechanism of natural product ingredients in the treatment of uveitis. J Immunol Res. 2021;2021:6683411.
   PubMed Web of Science ®Google Scholar
• Luo J, Jin DE, Yang GY, et al. Total glucosides of paeony for rheumatoid arthritis: a systematic review of randomized controlled trials. Complement Ther Med. 2017 Oct;34:46–56.
   PubMed Web of Science ®Google Scholar
• Xiong C, Qi J, Deng R, et al. Total glucosides of paeony inhibits proliferation and promotes activation- induced cell death of mouse T cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 2020 Jan 30;40(1):118–124.
   PubMedGoogle Scholar
• Wu W, He MF, Guo ZL, et al. Protective effect of total glucosides of paeony on uveitis model rats. Chin Pharm. 2014;25(11):994–996.
   Google Scholar
• Xu QB, Zhong LY, Zhu LW, et al. Adjuvant treatment of systemic lupus erythematosus with uveitis by total glucosides of paeony. Chin J Mod Appl Pharm. 2015;32(2):202–205.
   Google Scholar
• Jin L, Li C, Li Y, et al. Clinical efficacy and safety of total glucosides of paeony for primary Sjögren’s syndrome: a systematic review. Evid Based Complement Alternat Med. 2017;2017:3242301.
   PubMed Web of Science ®Google Scholar
• Ma G. Effect of Tripterygium wilfordii on recurrent uveitis. J Integr Ophthalmol. 1996;2:86–87.
   Google Scholar
• Huang QS, Zhang ZL, Liu YM. Effect of tripterygium wilfordii polyglycoside on serum IL-2 and TNF-alpha in patients with acute anterior U-veitis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 Jun;22(6):432–434.
   PubMedGoogle Scholar
• Song Q, Lu JZ, Li J. Effect of tripterygium glycosides on serum interleukin-1β, interleukin-2, tumor necrosis factor α, and interferon-γ levels in patients with Behcet’s disease. Chin J Integr Med. 2010;30(6):598–600.
   Google Scholar
• Yang HZ, Liu N, Dai C. Detection of endothelium function in patients with Behcet’disease and effect of tripterygium glycosides. Chin J Integr Dermatol Venereol. 2016;15(2):94–96.
   Google Scholar
• Liu B, Meng X, Ma Y, et al. Clinical safety of total glucosides of paeony adjuvant therapy for rheumatoid arthritis treatment: a systematic review and meta-analysis. BMC Complement Med Ther. 2021 Mar 26;21(1):102. doi: 10.1186/s12906-021-03252-y
   PubMedGoogle Scholar
• Song CY, Xu YG, Lu YQ. Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects. J Zhejiang Univ Sci B. 2020 Apr;21(4):280–290.
   PubMed Web of Science ®Google Scholar
• Tang K, Guo D, Zhang L, et al. Immunomodulatory effects of Longdan Xiegan Tang on CD4+/CD8+ T cells and associated inflammatory cytokines in rats with experimental autoimmune uveitis. Mol Med Rep. 2016 Sep;14(3):2746–54.
   PubMed Web of Science ®Google Scholar
• Yan SK, Xin WF, Luo GA, et al. Simultaneous determination of major bioactive components in qingkailing injection by high-performance liquid chromatography with evaporative light scattering detection. Chem Pharm Bull (Tokyo). 2005 Nov;53(11):1392–5.
   PubMed Web of Science ®Google Scholar
• Tian Q, Bi H, Cui Y, et al. Qingkailing injection alleviates experimental autoimmune uveitis in rats via inhibiting Th1 and Th17 effector cells. Biol Pharm Bull. 2012;35(11):1991–6. doi: 10.1248/bpb.b12-00449
   PubMed Web of Science ®Google Scholar
• Song J, Tian Q, Lu D, et al. Clinical study on treatment of chronic uveitis with Qinghuo Rougan Mingmu formula. Chin J Chin Ophthal. 2017;27:158–162.
   Google Scholar
• Jing C, Sun Z, Xie X, et al. Network pharmacology-based identification of the key mechanism of Qinghuo Rougan Formula acting on uveitis. Biomed Pharmacother. 2019 Dec;120:109381.
   PubMed Web of Science ®Google Scholar
• Xu H, Liu M, Cao J, et al. The Dynamic Interplay between the gut microbiota and autoimmune diseases. J Immunol Res. 2019;2019:7546047.
   PubMed Web of Science ®Google Scholar
• Kalyana Chakravarthy S, Jayasudha R, Sai Prashanthi G, et al. Dysbiosis in the gut bacterial microbiome of patients with Uveitis, an inflammatory disease of the eye. Indian J Microbiol. 2018 Dec;58(4):457–469.
   PubMed Web of Science ®Google Scholar
• Huang X, Ye Z, Cao Q, et al. Gut microbiota composition and fecal metabolic phenotype in patients with acute anterior uveitis. Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1523–1531. doi: 10.1167/iovs.17-22677
   PubMed Web of Science ®Google Scholar
• Janetos TM, Zakaria N, Goldstein DA. The microbiome and uveitis: a narrative review. Am J Pathol. 2023 Apr 5;193(11):1638–1647.
   PubMed Web of Science ®Google Scholar
• Kim J, Choi SH, Kim YJ, et al. Clinical effect of IRT-5 probiotics on immune modulation of autoimmunity or alloimmunity in the eye. Nutrients. 2017 Oct 25;9(11):1166.
   PubMed Web of Science ®Google Scholar
• Llop SM, Davoudi S, Stanwyck LK, et al. Association of Low Vitamin D Levels with noninfectious uveitis and Scleritis. Ocul Immunol Inflamm. 2019;27(4):602–609. doi: 10.1080/09273948.2018.1434208
   PubMed Web of Science ®Google Scholar
• Susarla G, Chan W, Li A, et al. Mendelian randomization shows a causal effect of low vitamin D on Non-infectious Uveitis and scleritis risk. Am J Ophthalmol. 2022 Dec;244:11–18.
   PubMed Web of Science ®Google Scholar
• Chiu ZK, Lim LL, Rogers SL, et al. Patterns of vitamin D levels and exposures in active and inactive noninfectious uveitis patients. Ophthalmol. 2020 Feb;127(2):230–237.
   PubMed Web of Science ®Google Scholar
• Noyan T, Sahin I, Sekeroğlu MR, et al. The serum vitamin C levels in Behçet’s disease. Yonsei Med J. 2003 Oct 30;44(5):771–8. doi: 10.3349/ymj.2003.44.5.771
   PubMed Web of Science ®Google Scholar
• Kükner AS, Kükner A, Naziroğlu M, et al. Protective effects of intraperitoneal vitamin C, aprotinin and melatonin administration on retinal edema during experimental uveitis in the guinea pig. Cell Biochem Funct. 2004 Sep;22(5):299–305.
   PubMed Web of Science ®Google Scholar
• Pararajasegaram G, Sevanian A, NA R. Suppression of S antigen-induced uveitis by vitamin E supplementation. Ophthalmic Res. 2009;23(3):121–127.
   Google Scholar
• Nussenblatt RB, Kim J, Thompson DJ, et al. Vitamin E in the treatment of uveitis-associated macular edema. Am J Ophthalmol. 2006 Jan;141(1):193–194.
   PubMed Web of Science ®Google Scholar
• van Rooij J, Schwartzenberg SG, Mulder PG, et al. Oral vitamins C and E as additional treatment in patients with acute anterior uveitis: a randomised double masked study in 145 patients. Br J Ophthalmol. 1999 Nov;83(11):1277–1282.
   PubMed Web of Science ®Google Scholar
• Hewlings SJ, DS K. Curcumin: a review of its effects on human health. Foods. 2017 Oct 22;6(10):92.
   PubMed Web of Science ®Google Scholar
• Wang M, Wang Z, Liu Y, et al. The effectiveness and safety of total glucosides of paeony in systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2022 Dec 16;101(50):e32029. doi: 10.1097/MD.0000000000032029
   PubMed Web of Science ®Google Scholar
• Li Q, Huang Y, Liu P, et al. Effect of tripterygium wilfordii polyglycoside tablets on serum inflammatory factors and T cells in patients with chronic nephritis. Am J Transl Res. 2021;13(7):8385–8390.
   PubMed Web of Science ®Google Scholar
• Smeele HTW, Röder E, AGMGJ M, et al. Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients’ offspring. Ann Rheumatic Dis. 2022;81(10):1367–1373.
   PubMed Web of Science ®Google Scholar